Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan
- 95 Downloads
Squamous cell carcinoma of the lung is associated with smoking in its development and comprises about 20–30% of all lung cancers. Its treatment strategy had been limited for the past decades, inevitably resulting in the poor outcome. However in the 2010s, it has dramatically changed mainly with the recent clinical introduction of immune checkpoint inhibitors. In this review, we will introduce various clinical studies involving squamous cell carcinoma of the lung.
KeywordsSquamous cell carcinoma of the lung Cytotoxic drug Immune checkpoint inhibitor
This article is a secondary publication of the review article “Treatment for Advanced Squamous Cell Carcinoma of the Lung” accepted to Japanese Journal of Lung Cancer 2018 vol 58, page 325–330 in 2018.
Compliance with ethical standards
Conflict of interest
Satoru Senoo has no conflicts of interest. Kiichiro Ninomiya received honoraria from Astrazeneca, MSD, Bristol-Myers Squibb, and Ono pharmaceutical. Katsuyuki Hotta received honoraria from Astrazeneca, and MSD, and research funding from Chugai pharmaceutical, Eli Lilly Japan, Bristol-Myers Squibb, and Astellas Pharma. Katsuyuki Kiura received honoraria from Astrazeneca, and Eli Lilly Japan, and research funding from Astrazeneca, and Chugai pharmaceutical.
- 2.National Cancer Institute: SEER Cancer Statistics Review: Available via DIALOG https://seer.cancer.gov/. Accessed May 2018
- 9.Hotta K, Ninomiya K, Takigawa N et al (2015) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol 45:603–604Google Scholar
- 12.Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191CrossRefGoogle Scholar
- 14.Thatcher N, Hirsch FR, Luft AV et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16:763–774CrossRefGoogle Scholar
- 15.Yoshioka H, Watanabe S, Sakai H et al (2018) Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): an open-label randomized multicenter phase Ib-II trial in Japan. ASCO 2018 (Abs 9038)Google Scholar
- 18.Kato Y, Hotta K, Takigawa N et al (2014) Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 73:943–950CrossRefGoogle Scholar
- 24.Oda N, Hotta K, Yoshioka H et al (2016) Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 78:941–947CrossRefGoogle Scholar
- 31.Japanese Lung Cancer Society (2017) EBM no shuho ni yoru haigan shinryo guideline. Kanehara &Co. Ltd., TokyoGoogle Scholar
- 33.Hotta K, Kiura K, Takigawa N et al (2010) Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol 5:179–184CrossRefGoogle Scholar
- 38.Lopes G, Wu YL, Kudaba I et al (2018) Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study. ASCO 2018 (Abs LBA4)Google Scholar
- 40.Jotte RM, Cappuzzo F, Vynnychenko I et al (2018) IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. ASCO 2018 (Abs LBA9000)Google Scholar
- 41.Socinski MA, Rittmeyer A, Shapovalov D et al (2018) IMpower131: progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. ESMO 2018Google Scholar
- 47.Gadgeel S, Kowanetz F, Zou W et al (2017) Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L + NSCLC: results from the randomized OAK study. ESMO 2017 (Abs 1296O)Google Scholar
- 48.Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673CrossRefGoogle Scholar
- 51.Rizvi H, Sanchez-Vega F, La K et al (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36:633–641CrossRefGoogle Scholar
- 55.Hodi FS, Chiarion-Sileni V, Gonzalez R et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30700-9 (epub ahead of print) Google Scholar